NanoViricides has entered into an agreement with Baylor College of Medicine for the testing of its nanoviricides® drug candidates in a small animal model of ocular virus infections.

These animal studies will evaluate the efficacy and potency of the nanoviricides® anti-viral agents in certain ocular viral infections. The goal of these studies is to help select clinical drug development candidates for treatment of certain ocular viral diseases including herpes keratitis in humans.